Phage therapy: Where East meets West

Expert Review of Anti-Infective Therapy

Volumn 2, Issue 6, 2004, Pages 815-819

  Debattista, Joseph ^a  

^a THE PRINCE CHARLES HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERICIDE; DNA; PENICILLIN G; SULFONAMIDE;

ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BACTERIOLYSIS; BACTERIOPHAGE; CELL LYSATE; CHOLERA; DRUG EFFICACY; DRUG RESEARCH; EDITORIAL; ENTEROCOCCUS; GENE EXPRESSION; GENETIC CODE; HISTORY; HUMAN; MULTIDRUG RESISTANCE; NONHUMAN;

EID: 9944244956     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14789072.2.6.815     Document Type: Editorial

References (19)

1. Bruynghe R, Maisin J. Essais de therapeutique au moyen du bacteriophage du staphylocoque. C. R. Soc. Biol. 85, 1120-1121 (1921).
2. Krueger AP, Scribner EJ. The bacteriophage - its nature and its therapeutic use. J. Am. Med. Assoc. 116, 2160-2277 (1941).
3. Eaton MD, Bayne-Jones S. Bacteriophage therapy. J. Am. Med. Assoc. 103, 1769-1776, 1847-1853, 1934-1939 (1934).
4. Smith WH, Huggins MB. Successful treatment of experimental Escherichia coli infections in mice using phage: its general superiority over antibiotics. J. Gen. Microbiol. 128, 307-318 (1982).
5. Smith WH, Huggins MB. Effectiveness of phage in treating experimental Escherichia coli diarrhea in calves, piglets and lambs. J. Gen. Microbiol. 129, 659-675 (1983).
6. Mulczyk M, Slopek S. Use of a new phage preparation in prophylaxis and treatment of shigellosis. Acta Microbiol. Acad. Sci. Hung. 21, 115-119 (1974).
7. Slopek S, Dutlakowa I, Weber-Dabrowska B et al. Results of bacteriophage treatment of suppurative bacterial infections. Arch. Immunol. Ther. Exp. 31, 267-327 (1983).
8. Slopek S, Durlakowa I, Weber-Dabrowska B et al. Results of bacteriophage treatment of suppurative bacterial infections III. Detailed evaluation of the results obtained in further 150 cases. Arch. Immunol. Ther. Exp. 32(3), 317-335 (1984).
9. Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B et al. Results of bacteriophage treatment of suppurative bacterial infections. Evaluation of the results obtained in 370 cases. Arch. Immunol. Ther. Exp. 33(2), 219-240 (1985).
10. Slopek S, Kucharewicz-Krukowska A, Weber-Dabrowska B et al. Results of bacteriophage treatment of suppurative bacterial infections. Evaluation of the results obtained in children. Arch. Immunol. Ther. Exp. 33(2), 241-259 (1985).
11. Cislo M, Dabrowski M, Weber-Dabrowska B. Bacteriophage treatment of suppurative skin infections. Arch. Immunol. Ther. Exp. 35, 175-183 (1987).
12. Weber-Dubrowska B, Mulczyk M, Gorski A. Bacteriphage therapy of bacterial infections: an update of our institute's experience. Arch. Immunol. Ther. Exp. 48, 547-551 (2000).
13. Kochetkova VA, Mamontov AS, Moskovtseva RL et al. Phagotherapy of postoperative suppurative-inflammatory complications in patients with neoplasms. Sovetskaya Meditsina 6, 23-26 (1989).
14. Bogovazova GG, Voroshilova NN, Bondarenko VM et al. Immunobiological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages. Zhurnal Mikrobiol. Epidemiol. Immunobiol. 3, 30-33 (1992).
15. Merril CR, Biswas B, Carlton R et al. Long-circulating bacteriphage as antibacterial agents. Proc. Natl Acad. Sci. USA 93, 388-392 (1996)
16. Biswas B, Adhya S, Washart P et al. Bacteriphage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70, 204-210 (2002).
17. Doulatov S, Hodes A, Dai L et al. Tropism switching in bordetella bacteriphage defines a family of diversity-generating retro-elements. Nature 43, 476-481 (2004).
18. Westwater C, Kasman LM, Schofield DA et al. Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections. Antimicrob. Agents Chemother. 47, 1301-1307 (2003).
19. Jado I, Lopez R, Garcia E et al. Phage lytic enzymes as therapy for antibiotic-resistant Streptocococcus pneumoniae infection in a murine sepsis model. J. Antimicrob. Chemother. 52, 967-973 (2003).